Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis

Autor: Berkovich, Regina, Negroski, Donald, Wynn, Daniel, Sellers, Daniel, Bzdek, Kristen G., Lublin, Alex L., Rawlings, Andreea M., Quach, Cuc, Wells, Danelle P., Dumlao, Melanie, Bora, Adriana, Ranno, Anthony E., Luo, Kevin Lin, Chavin, Jeffrey, Hua, Le H., Becker, Daniel

Publikováno v: In Multiple Sclerosis and Related Disorders February 2023 70

3.30 Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in the Treatment of Irritability-Related Behavioral Symptoms in Children, Adolescents, and Young Adults With Fragile X Syndrome: Update to Open-Label Extension Study

Autor: Bzdek, Kristen G., Thibodeau, Anthony, Tich, Nancy, Albers, David, Nomikos, George

Publikováno v: In Journal of the American Academy of Child & Adolescent Psychiatry October 2024 63(10) Supplement:S215-S215

Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States.

Autor: Araujo L; Neurology and Immunology, Sanofi, Cambridge, MA, USA., Kyatham S; Axtria Inc, Berkeley Heights, NJ, USA., Bzdek KG; Neurology and Immunology, Sanofi, Cambridge, MA, USA., Higuchi K; Neurology and Immunology, Sanofi, Cambridge, MA, USA., Greene N; Neurology and Immunology, Sanofi, Cambridge, MA, USA.

Publikováno v: ClinicoEconomics and outcomes research : CEOR [Clinicoecon Outcomes Res] 2023 May 20; Vol. 15, pp. 361-373. Date of Electronic Publication: 2023 May 20 (Print Publication: 2023).